TRPV1 and myeloid sarcoma: Moreover, we determined that the levels of pCREB (Fig. 3H; 127.48 ± 9.5, p < 0.05) and pNFκB (Fig. 3I; 126.39 ± 8.41, p < 0.05) were significantly increased in the MS group compared with those in the control group, and further attenuated in the EA group (Fig. 3H and I, 96.23 ± 7.83; 92.98 ± 7.08, respectively, p < 0.05) and TRPV1−/− group (Fig. 3H and I; 91.92 ± 10.42; 102.70 ± 7.23, respectively, p < 0.05) compared with those in the MS group.